Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer

[1]  Petra Macaskill,et al.  Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. , 2012, European journal of cancer.

[2]  Nola Hylton,et al.  Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  G. Minckwitz,et al.  Neoadjuvant chemotherapy in breast cancer—insights from the German experience , 2012, Breast Cancer.

[4]  P. Fasching,et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Tutt,et al.  Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer , 2012, Annals of Surgical Oncology.

[6]  S. Rodenhuis,et al.  Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics , 2012, Breast Cancer Research and Treatment.

[7]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[8]  Peter A Fasching,et al.  Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment , 2011, BMC Cancer.

[9]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Satoru Takahashi,et al.  High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer , 2011, International Journal of Clinical Oncology.

[11]  M. Piccart-Gebhart.  New developments in hormone receptor-positive disease. , 2010, The oncologist.

[12]  A. Luini,et al.  Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features , 2010, Breast Cancer Research and Treatment.

[13]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[14]  K. Gelmon,et al.  Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.

[15]  Satoru Takahashi,et al.  Predictors of response to exemestane as primary endocrine therapy in estrogen receptor–positive breast cancer , 2009, Cancer science.

[16]  Robin L. Jones,et al.  The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer , 2009, Breast Cancer Research and Treatment.

[17]  F. Penault-Llorca,et al.  Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C. Perou,et al.  Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Gelber,et al.  Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. , 2008, Journal of the National Cancer Institute.

[20]  Andreas Makris,et al.  Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer , 2006, Breast Cancer Research.

[21]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[22]  H. Mukai,et al.  Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer , 2012, Breast Cancer Research and Treatment.

[23]  T. Onda.  [Neoadjuvant chemotherapy]. , 2012, Nihon rinsho. Japanese journal of clinical medicine.

[24]  M. Piccart-Gebhart.  New developments in hormone receptor-positive disease. , 2010, The oncologist.

[25]  Robin L. Jones,et al.  Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer , 2009, Breast Cancer Research and Treatment.

[26]  H. Tsuda,et al.  Histopathological criteria for assessment of therapeutic response in breast cancer (2007 version) , 2008, Breast cancer.

[27]  H. Tsuda,et al.  Histopathological criteria for assessment of therapeutic response in breast cancer , 2001, Breast cancer.